An interventional study of Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes in Diabetes Mellitus, sponsored by Ascensia Diabetes Care. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-18.
Sponsored by Ascensia Diabetes Care · Not applicable, Interventional, and Supportive care
This study will collect lay user ("subjects") and healthcare professional information on the performance of two different blood glucose monitors, the CONTOUR NEXT and the CONTOUR TV3, in people with and without diabetes. Each subject will use both meters, at different times and in different order, using a fingerstick(s) to collect meter samples. Meter results will be compared to standardized test system to assess the accuracy of the meters' results. Additionally, a blood sample will be drawn from the subject's arm by a trained healthcare professional for testing on both BGMS. Subjects will also be asked to complete a questionnaire to rate their experience using the meters and to evaluate the meter's Instructions for Use. After all testing and the first questionnaire have been completed, the study staff will demonstrate only to subjects with diabetes several features of the meters that would not necessarily be experienced during the meter testing. These subjects will then answer questions about the features in a second questionnaire.
This clinical trial will assess the performance (accuracy) of the CONTOUR NEXT and the CONTOUR TV3 monitoring systems ("BGMS") by lay users enrolled as subjects in the study, and by health care professionals. According to a randomization schedule, subjects will be assigned to use either the CONTOUR NEXT or CONTOUR TV3 meters first and then switch and use the second meter, performing the same testing with both meters. They will learn to use the assigned meter by reading the corresponding User Guide (UG) and Quick Reference Guide (QRG). Each subject will perform one fingerstick self-test a palm (AST) test and the study staff will perform a fingerstick test on the subject. All subject self-test results and study staff results will be compared to results from the reference analyzer from a deeper fingerstick. Hematocrit will be measured for all subjects. After testing, all subjects will then complete a questionnaire (Questionnaire 1) to provide feedback on the meter system and instructions for use (UG and QRG). Subjects with diabetes will also have their glucose tested via venipuncture. After all testing is completed on these subjects, the study staff will demonstrate several features of the meter system that would not necessarily be experienced during the brief accuracy testing. These subjects with diabetes will be given a second questionnaire (Questionnaire 2) to provide feedback about the new features of the system. After completing the study procedures for one BGMS, all subjects will then repeat all of these procedures using the second BGMS, except the hematocrit and venipuncture procedures.
Ascensia Diabetes Care is the lead sponsor of 42 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All subjects test CONTOUR NEXT BGMS and CONTOUR TV3 BGMS
Device: Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes
Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer
Number of Participants with self fingerstick results from the Contour Next BGMS and Contour TV3 BGMS that are within 15% of results from the Reference Analyzer. Results from the two meter systems will not be compared to each other.
Time frame: 1 day
Subjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMS
A questionnaire was given to participants with 8 statements about the BGMS instructions for use and ease of use of the meter system. These statements were rated by subjects on a Likert Scale with ratings of 1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree. Participants reporting ratings greater than or equal to 3 are reported. The statements are: 1. I find it easy to do a fingerstick blood test with this meter. 2. The meter display is easy to see and read. 3. It was easy to understand my test results. 4. I like the overall meter design. 5. I find the meter easy to use. 6. The instructions (User Guide and Quick Reference Guide) were easy to understand. 7. The instructions clearly explain how to run a test. 8. The instructions clearly explain what to do if an error message is displayed by the meter. Note that results from the two meter systems will not be compared to each other.
Time frame: 1 day
Persons with and without diabetes were enrolled in the study from September 06, 2018 to October 31, 2018. These subjects had one visit to the clinical trial center for the study.
| Milestone | Contour Next and Contour TV3 -Subjects With and Without Diabetes |
|---|---|
| Started | 372 |
| Completed | 371 |
| Not completed | 1 |
| Withdrew: Meter displayed a hi result which is non evaluable. | 1 |
Number of Participants with self fingerstick results from the Contour Next BGMS and Contour TV3 BGMS that are within 15% of results from the Reference Analyzer. Results from the two meter systems will not be compared to each other.
| Participants | Contour Next and Contour TV3 -Subjects With and Without Diabetes |
|---|---|
| Contour Next Contour Next BGMS | 366 |
| Contour TV3 BGMS | 360 |
A questionnaire was given to participants with 8 statements about the BGMS instructions for use and ease of use of the meter system. These statements were rated by subjects on a Likert Scale with ratings of 1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree. Participants reporting ratings greater than or equal to 3 are reported. The statements are: 1. I find it easy to do a fingerstick blood test with this meter. 2. The meter display is easy to see and read. 3. It was easy to understand my test results. 4. I like the overall meter design. 5. I find the meter easy to use. 6. The instructions (User Guide and Quick Reference Guide) were easy to understand. 7. The instructions clearly explain how to run a test. 8. The instructions clearly explain what to do if an error message is displayed by the meter. Note that results from the two meter systems will not be compared to each other.
| Participants | Contour Next BGMS and Contour TV3 BGMS-Subjects With and Without Diabetes |
|---|---|
| Contour Next: Responses greater than or equal to 3 for Statement 1 | 371 |
| Contour Next: Responses greater than or equal to 3 for Statement 2 | 371 |
| Contour Next: Responses greater than or equal to 3 for Statement 3 | 370 |
| Contour Next: Responses greater than or equal to 3 for Statement 4 | 359 |
| Contour Next: Responses greater than or equal to 3 for Statement 5 | 371 |
| Contour Next: Responses greater than or equal to 3 for Statement 6 | 367 |
| Contour Next: Responses greater than or equal to 3 for Statement 7 | 368 |
| Contour Next: Responses greater than or equal to 3 for Statement 8 | 368 |
| Contour TV3: Responses greater than or equal to 3 for Statement 1 | 369 |
| Contour TV3: Responses greater than or equal to 3 for Statement 2 | 370 |
| Contour TV3: Responses greater than or equal to 3 for Statement 3 | 369 |
| Contour TV3: Responses greater than or equal to 3 for Statement 4 | 353 |
| Contour TV3: Responses greater than or equal to 3 for Statement 5 | 370 |
| Contour TV3: Responses greater than or equal to 3 for Statement 6 | 369 |
| Contour TV3: Responses greater than or equal to 3 for Statement 7 | 370 |
| Contour TV3: Responses greater than or equal to 3 for Statement 8 | 368 |
Collected over 1 day.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes | 0/372 (0%) | 0/372 (0%) | 2/372 (0.5%) |
| Event | Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes |
|---|---|
| Vasovagal ReactionGeneral disorders | 1/372 |
| FaintingGeneral disorders | 1/372 |
| Age, Categorical(Participants) | Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 295 |
| >=65 years | 76 |
| Age, Continuous(years) | Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes |
|---|---|
| mean age | 53.1 ± 14.86 |
| Sex: Female, Male(Participants) | Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes |
|---|---|
| Female | 206 |
| Male | 166 |
| Ethnicity (NIH/OMB)(Participants) | Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes |
|---|---|
| Hispanic or Latino | 49 |
| Not Hispanic or Latino | 323 |
| Unknown or Not Reported | 0 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ascensia Diabetes Care